Insider · CIK 0001283303

REED ELIZABETH E

Reports to the SEC for 3 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001283303

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-15	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	+37.5K sh	$15.46	+$580K	142,889
2026-09-15	TVTXTravere Therapeutics, Inc.S Sale	Chief Legal Officer and GC	SSale	−21.9K sh	$62.03	−$1.36M	120,963
2026-09-15	TVTXTravere Therapeutics, Inc.S Sale	Chief Legal Officer and GC	SSale	−13.9K sh	$62.63	−$869K	107,089
2026-09-15	TVTXTravere Therapeutics, Inc.S Sale	Chief Legal Officer and GC	SSale	−1,400 sh	$63.69	−$89.2K	105,689
2026-09-15	TVTXTravere Therapeutics, Inc.S Sale	Chief Legal Officer and GC	SSale	−300 sh	$65.31	−$19.6K	105,389
2026-09-15	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	−37.5K sh	—	—	0
2026-05-06	TVTXTravere Therapeutics, Inc.S Sale	Chief Legal Officer and GC	SSale	−2,076 sh	$43.95	−$91.2K	105,211
2026-05-05	TVTXTravere Therapeutics, Inc.S Sale	Chief Legal Officer and GC	SSale	−2,174 sh	$46.65	−$101K	107,287
2026-05-04	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	+20K sh	$17.96	+$359K	125,211
2026-05-04	TVTXTravere Therapeutics, Inc.S Sale	Chief Legal Officer and GC	SSale	−20K sh	$45.00	−$900K	105,211
2026-05-04	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	+4,250 sh	—	—	109,461
2026-05-04	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	−20K sh	—	—	0
2026-05-04	TVTXTravere Therapeutics, Inc. · Performance-based restricted stock unitsA Award	Chief Legal Officer and GC	AAward	+8,500 sh	—	—	8,500
2026-05-04	TVTXTravere Therapeutics, Inc. · Performance-based restricted stock unitsM Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	−4,250 sh	—	—	4,250
2026-04-15	TVTXTravere Therapeutics, Inc.S Sale	Chief Legal Officer and GC	SSale	−5,226 sh	$41.62	−$218K	106,770
2026-04-15	TVTXTravere Therapeutics, Inc.S Sale	Chief Legal Officer and GC	SSale	−1,559 sh	$42.53	−$66.3K	105,211
2026-04-14	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	+10K sh	$19.08	+$191K	129,211
2026-04-14	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	+20K sh	$17.96	+$359K	149,211
2026-04-14	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	+7,500 sh	$15.46	+$116K	156,711
2026-04-14	TVTXTravere Therapeutics, Inc.S Sale	Chief Legal Officer and GC	SSale	−37.5K sh	$41.07	−$1.54M	119,211
2026-04-14	TVTXTravere Therapeutics, Inc.S Sale	Chief Legal Officer and GC	SSale	−7,215 sh	$41.93	−$303K	111,996
2026-04-14	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	−7,500 sh	—	—	37,500
2026-04-14	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	−10K sh	—	—	0
2026-04-14	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	−20K sh	—	—	20,000
2026-04-13	TVTXTravere Therapeutics, Inc.A Award	Chief Legal Officer and GC	AAward	+14K sh	—	—	119,211
2026-04-01	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	+10K sh	$15.46	+$155K	115,211
2026-04-01	TVTXTravere Therapeutics, Inc.S Sale	Chief Legal Officer and GC	SSale	−10K sh	$30.00	−$300K	105,211
2026-04-01	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	−10K sh	—	—	45,000
2026-03-16	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	+10K sh	$19.08	+$191K	115,211
2026-03-16	TVTXTravere Therapeutics, Inc.S Sale	Chief Legal Officer and GC	SSale	−10K sh	$28.09	−$281K	105,211
2026-03-16	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	−10K sh	—	—	10,000
2026-02-17	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	+10K sh	$19.08	+$191K	115,211
2026-02-17	TVTXTravere Therapeutics, Inc.S Sale	Chief Legal Officer and GC	SSale	−5,679 sh	$27.50	−$156K	109,532
2026-02-17	TVTXTravere Therapeutics, Inc.S Sale	Chief Legal Officer and GC	SSale	−4,321 sh	$28.26	−$122K	105,211
2026-02-17	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	−10K sh	—	—	20,000
2026-02-04	TVTXTravere Therapeutics, Inc.S Sale	Chief Legal Officer and GC	SSale	−2,485 sh	$32.07	−$79.7K	105,720
2026-02-04	TVTXTravere Therapeutics, Inc.S Sale	Chief Legal Officer and GC	SSale	−509 sh	$32.74	−$16.7K	105,211
2026-02-03	TVTXTravere Therapeutics, Inc.S Sale	Chief Legal Officer and GC	SSale	−7,175 sh	$32.12	−$230K	108,205
2026-01-31	TVTXTravere Therapeutics, Inc.A Award	Chief Legal Officer and GC	AAward	+25.1K sh	—	—	115,380
2026-01-31	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)A Award	Chief Legal Officer and GC	AAward	+67K sh	—	—	66,960
2026-01-20	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	+10K sh	$19.08	+$191K	100,270
2026-01-20	TVTXTravere Therapeutics, Inc.S Sale	Chief Legal Officer and GC	SSale	−10K sh	$27.34	−$273K	90,270
2026-01-20	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	−10K sh	—	—	30,000
2025-09-22	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	+10K sh	$19.08	+$191K	99,878
2025-09-22	TVTXTravere Therapeutics, Inc.S Sale	Chief Legal Officer and GC	SSale	−10K sh	$25.00	−$250K	89,878
2025-09-22	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	−10K sh	—	—	40,000
2025-05-05	TVTXTravere Therapeutics, Inc.S Sale	Chief Legal Officer and GC	SSale	−4,920 sh	$21.05	−$104K	89,482
2025-05-02	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	+4,920 sh	—	—	94,402
2025-05-02	TVTXTravere Therapeutics, Inc. · Performance-based restricted stock unitsM Exercise/Conversion	Chief Legal Officer and GC	MExercise/Conversion	−4,920 sh	—	—	4,920
2025-02-12	TVTXTravere Therapeutics, Inc.S Sale	Chief Legal Officer and GC	SSale	−8,000 sh	$23.53	−$188K	89,482

Recent filings

Accepted (ET)
Sep 174
REED ELIZABETH E0001283303-26-000010
SEC(opens sec.gov)
May 64
REED ELIZABETH E0001283303-26-000009
SEC(opens sec.gov)
Apr 154
REED ELIZABETH E0001283303-26-000008
SEC(opens sec.gov)

Companies

Address

C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DR., SUITE 300

SAN DIEGO, CA, 92130